Press release
Gonorrhoea Pipeline Outlook Report 2025: MOA, Companies, Companies, Clinical Trials, Expanding Therapeutic Classes, and Future Market Impact Revealed
Gonorrhoea Pipeline
Explore our latest breakthroughs in Gonorrhoea Research. Learn more about our innovative pipeline today! @ Gonorrhoea Pipeline Outlook- https://www.delveinsight.com/sample-request/gonorrhoea-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Gonorrhoea Pipeline Report
• DelveInsight's Gonorrhoea pipeline report depicts a robust space with 12+ active players working to develop 12+ pipeline therapies for Gonorrhoea treatment.
• The leading Gonorrhoea Companies such as Evofem Biosciences, GlaxoSmithKline, Entasis Therapeutics, Alopexx Pharmaceuticals, Nobelex Biotech, Summit Therapeutics, TherapyX, AchilleS Vaccines, Recce Pharmaceuticals, and VenatoRx Pharmaceuticals and others.
• Promising Gonorrhoea Pipeline Therapies such as Gepotidacin, Ceftriaxone, Azithromycin, GSK2140944, Solithromycin, Tinidazole and others.
Stay informed about the cutting-edge advancements in Gonorrhoea treatments. Download for updates and be a part of the revolution in Neurology Care @ Gonorrhoea Clinical Trials Assessment- https://www.delveinsight.com/sample-request/gonorrhoea-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
The Gonorrhoea Pipeline Report provides a disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Gonorrhoea Pipeline Report also highlights the unmet needs with respect to Gonorrhoea.
Gonorrhoea Overview
Gonorrhoea is a sexually transmitted infection (STI), usually passed on through unprotected vaginal, anal. It is caused by bacteria called Neisseria gonorrhoeae or gonococcus. Gonorrhoea used to be known as ""the clap"". Typical symptoms of gonorrhoea include a thick green or yellow discharge from the vagina, pain when peeing and, in women, bleeding between periods. Testing for gonorrhea is done by swabbing the infected site, throat, and cervix) and identifying the bacteria in the laboratory. Gonorrhoea is usually treated with a single antibiotic injection or a single antibiotic tablet.
Gonorrhoea Emerging Drugs Profile
• Gepotidacin: GlaxoSmithKline
Gepotidacin (GSK2140944) belongs to class of antibiotics, called triazaacenaphthylene topoisomerase inhibitors. Gepotidacin works by selectively interacting with two key bacterial enzymes, DNA gyrase and topoisomerase IV (type II topoisomerases), responsible for bacterial replication. The novel MOA confers activity against most target pathogens resistant to established antibiotics, including fluoroquinolones. The drug is in Phase III clinical studies for the treatment of uncomplicated urinary tract infection (uUTI)/gonorrhea.
• Zoliflodacin: Entasis Therapeutics
Zoliflodacin (ETX0914) is an orally bioavailable antibacterial agent. It is a novel spiropyrimidinetrione bacterial DNA gyrase/topoisomerase inhibitor. The drug is in Phase III clinical developmental studies for the treatment of Gonorrhoea.
The Gonorrhoea Pipeline Report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Gonorrhoea with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Gonorrhoea Treatment.
• Gonorrhoea Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Gonorrhoea Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Gonorrhoea market.
Learn more about Gonorrhoea Drugs opportunities in our groundbreaking Gonorrhoea research and development projects @ Gonorrhoea Unmet Needs- https://www.delveinsight.com/sample-request/gonorrhoea-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Gonorrhoea Companies
Evofem Biosciences, GlaxoSmithKline, Entasis Therapeutics, Alopexx Pharmaceuticals, Nobelex Biotech, Summit Therapeutics, TherapyX, AchilleS Vaccines, Recce Pharmaceuticals, and VenatoRx Pharmaceuticals and others.
Gonorrhoea Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical
• Molecule Type
Gonorrhoea Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type
Discover the latest advancements in Gonorrhoea treatment by visiting our website. Stay informed about how we're transforming the future of Neurology @ Gonorrhoea Market Drivers and Barriers, and Future Perspectives- https://www.delveinsight.com/sample-request/gonorrhoea-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Gonorrhoea Pipeline Report
• Coverage- Global
• Gonorrhoea Companies- Evofem Biosciences, GlaxoSmithKline, Entasis Therapeutics, Alopexx Pharmaceuticals, Nobelex Biotech, Summit Therapeutics, TherapyX, AchilleS Vaccines, Recce Pharmaceuticals, and VenatoRx Pharmaceuticals and others.
• Gonorrhoea Pipeline Therapies- Gepotidacin, Ceftriaxone, Azithromycin, GSK2140944, Solithromycin, Tinidazole and others.
• Gonorrhoea Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Gonorrhoea Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Gonorrhoea Pipeline on our website, @ Gonorrhoea Emerging Drugs and Companies
Table of Contents
1. Introduction
2. Executive Summary
3. Gonorrhoea: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Gonorrhoea - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. Gonorrhoea Collaboration Deals
9. Late Stage Products (Phase III)
10. Gepotidacin: GlaxoSmithKline
11. Mid Stage Products (Phase II)
12. F 598: Alopexx Pharmaceuticals
13. Early Stage Products (Phase I)
14. Drug name: Company name
15. Preclinical/Discovery Stage Products
16. GneX 12: TherapyX
17. Inactive Products
18. Gonorrhoea Key Companies
19. Gonorrhoea Key Products
20. Gonorrhoea- Unmet Needs
21. Gonorrhoea- Market Drivers and Barriers
22. Gonorrhoea- Future Perspectives and Conclusion
23. Gonorrhoea Analyst Views
24. Gonorrhoea Key Companies
25. Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Gonorrhoea Pipeline Outlook Report 2025: MOA, Companies, Companies, Clinical Trials, Expanding Therapeutic Classes, and Future Market Impact Revealed here
News-ID: 4280034 • Views: …
More Releases from DelveInsight Business Research LLP
Glioblastoma Multiforme Market Size (7MM) was ~USD 835 million in 2023 and is ex …
DelveInsight's "Glioblastoma Multiforme Market Insight, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of GBM, historical and forecasted epidemiology as well as the GBM market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Discover Key Insights into the Glioblastoma Multiforme Market with DelveInsight's In-Depth Report @ Glioblastoma Multiforme Market Size- https://www.delveinsight.com/sample-request/glioblastoma-multiforme-gbm-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Glioblastoma Multiforme Market Report
• In…
Blepharitis Treatment Market Size in the 7MM is expected to grow by 2034, estima …
DelveInsight's "Blepharitis Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of Blepharitis, historical and forecasted epidemiology, as well as the Blepharitis market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Explore the intricate details of the Blepharitis Market: Uncover drug uptake, treatment dynamics, and epidemiological trends with our comprehensive Blepharitis Market Forecast @ https://www.delveinsight.com/sample-request/blepharitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from…
CAR-T in NHL Treatment Market Size is estimated to grow by 2034, estimates Delve …
DelveInsight's "CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of CAR T-Cell Therapy for Non-Hodgkin's Lymphoma, historical and forecasted epidemiology, as well as the CAR T-Cell Therapy for Non-Hodgkin's Lymphoma market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Explore the intricate details of the CAR T-Cell Therapy for Non-Hodgkin's Lymphoma…
Parkinson's Disease Psychosis Market Size (7MM) was ~USD 665 million in 2023 and …
DelveInsight's "Parkinson's Disease Psychosis Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of Parkinson's Disease Psychosis, historical and forecasted epidemiology, as well as the Parkinson's Disease Psychosis market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Explore the intricate details of the Parkinson's Disease Psychosis Market: Uncover drug uptake, treatment dynamics, and epidemiological trends with our comprehensive…
More Releases for Gonorrhoea
CT/NG Testing Market Projected to Grow at 8.1% CAGR, Surpassing USD 3.2 Billion …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global CT/NG Testing Market- (By Product (Assays & kits, Instruments/Analyzers), By Test Type (Laboratory, Point-of-care testing), By Technology (INAAT, PCR, Immunodiagnostics, Others), By End-User (Diagnostics & Laboratories, Hospitals & Clinics, Others)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."
According to the latest research by InsightAce Analytic, the Global CT/NG Testing Market is valued at US$…
CT/NG Testing Market Projected to Grow at 8.1% CAGR, Surpassing USD 3.2 Billion …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global CT/NG Testing Market- (By Product (Assays & kits, Instruments/Analyzers), By Test Type (Laboratory, Point-of-care testing), By Technology (INAAT, PCR, Immunodiagnostics, Others), By End-User (Diagnostics & Laboratories, Hospitals & Clinics, Others)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."
According to the latest research by InsightAce Analytic, the Global CT/NG Testing Market is valued at US$…
Gonorrhea Treatment Market Size, Share, Report and Forecast 2024-2032
Gonorrhea Treatment Market Outlook
The gonorrhea treatment market was estimated to be worth USD 1.48 billion in 2023. The market is likely to grow at a rate of 4.7% in the forecasted period 2024-2032. Within this growth rate, the market value is estimated to reach about USD 2.24 billion by 2032. The market is primarily driven by the increased prevalence of sexually transmitted infections and the expected launch of novel therapies.
Gonorrhea…
Gonorrhea Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 12+ key pharma and biotech companies are working on 12+ pipeline drugs in the Gonorrhea therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
"Gonorrhea Pipeline Insight, 2023" report by DelveInsight…
CT/NG Testing Market - Know the Untapped Revenue Growth Opportunities
CT/NG Testing Market worth $3.27 Bn by 2031 - Exclusive Report by InsightAce Analytic Pvt. Ltd.
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global CT/NG Testing Market- (By Product (Assays & kits, Instruments/Analyzers), By Test Type (Laboratory, Point-of-care testing), By Technology (INAAT, PCR, Immunodiagnostics, Others), By End-User (Diagnostics & Laboratories, Hospitals & Clinics, Others)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."
According to…
Gonorrhoea Market Size was approximately USD XX Million in 2022, estimates Delve …
"The Gonorrhoea Market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period (2023-2032). Furthermore, launching various multiple- Gonorrhoea pipeline products will significantly revolutionize the Gonorrhoea market dynamics"
The Gonorrhoea market report provides current treatment practices, Gonorrhoea emerging drugs, market share of individual therapies, and current and forecasted 7MM a Gonorrhoea market size from 2019 to 2032. The report also covers current Gonorrhoea treatment…
